Kaminsky S, Laniado M, Gogoll M, Kornmesser W, Clauss W, Felix R
Klinikum Rudolf Virchow, Standort Charlottenburg, Strahlenklinik und Poliklinik, Freie Universität Berlin.
Rofo. 1992 Jan;156(1):17-23. doi: 10.1055/s-2008-1032829.
Safety and efficacy of gadopentetate-dimeglumine (Gd-DTPA) as a MR bowel contrast agent were determined in 133 patients with CT-proved abdominal and retroperitoneal mass lesions using a buffered formulation (1 mmol/l Gd-DTPA, 15 g/l mannitol, 25 mmol/l sodium-citrate, 6-17 ml/kg). Short-lived gastrointestinal side effects were noted in 32% of patients. Gd-DTPA provided uniform, hyperintense bowel labelling and contrast enhancement in the region of interest in 81% of patients. Among 78 patients with pre- and postcontrast images lesion delineation was improved in 62%. In 55 studies with postcontrast images only, Gd-DTPA proved useful in 65%. In 105 of 109 cases IV injection of scopolamine or glucagon eliminated image artifacts arising from peristalsis of opacified bowel. The authors conclude that Gd-DTPA is a safe and effective MR bowel contrast agent.
使用一种缓冲制剂（1毫摩尔/升钆喷酸葡胺、15克/升甘露醇、25毫摩尔/升柠檬酸钠，6 - 17毫升/千克），在133例经CT证实有腹部和腹膜后肿块病变的患者中确定了钆喷酸葡胺（Gd - DTPA）作为磁共振肠道造影剂的安全性和有效性。32%的患者出现了短暂的胃肠道副作用。Gd - DTPA在81%的患者中使感兴趣区域的肠道标记均匀且呈高信号，并增强了对比度。在有增强前后图像的78例患者中，62%的患者病变轮廓得到改善。在仅具有增强后图像的55项研究中，Gd - DTPA在65%的研究中被证明是有用的。在109例中的105例中，静脉注射东莨菪碱或胰高血糖素消除了由显影肠道蠕动引起的图像伪影。作者得出结论，Gd - DTPA是一种安全有效的磁共振肠道造影剂。
